These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 3346746)

  • 1. Human breast milk excretion of iodine-131 following diagnostic and therapeutic administration to a lactating patient with Graves' disease.
    Dydek GJ; Blue PW
    J Nucl Med; 1988 Mar; 29(3):407-10. PubMed ID: 3346746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I.
    Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
    Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simplified method for treating Graves' disease with radioactive 131I.
    Masri MT; Menne M; Rooney BL; Caplan RH
    Wis Med J; 1995 Jan; 94(1):21-5. PubMed ID: 7871797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term carbimazole intake does not affect success rate of radioactive 131Iodine in treatment of Graves' hyperthyroidism.
    El Refaei SM; Shawkat W
    Nucl Med Commun; 2008 Jul; 29(7):642-8. PubMed ID: 18528187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Administration of additional inactive iodide during radioiodine therapy for Graves' disease: who might benefit?
    Dietlein M; Moka D; Reinholz U; Schmidt M; Schomäcker K; Schicha H; Wellner U
    Nuklearmedizin; 2007; 46(3):77-84. PubMed ID: 17549318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
    Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iodine-131 in breast milk following therapy for thyroid carcinoma.
    Robinson PS; Barker P; Campbell A; Henson P; Surveyor I; Young PR
    J Nucl Med; 1994 Nov; 35(11):1797-801. PubMed ID: 7965159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
    Berg GE; Michanek AM; Holmberg EC; Fink M
    J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Results of treatment of Graves-Basedow disease with 131I at low calculated doses].
    Gómez Arnaiz N; Gómez Saez JM; Orti Llavería A; Gavaldá Mestre L; Mairal Pairó L; Soler Ramón J
    Rev Clin Esp; 1998 Feb; 198(2):57-60. PubMed ID: 9558917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioactive iodine in the treatment of Graves' disease.
    Al-Kaabi JM; Hussein SS; Bukheit CS; Woodhouse NJ; Elshafie OT; Bererhi H
    Saudi Med J; 2002 Sep; 23(9):1049-53. PubMed ID: 12370710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast milk excretion of radiopharmaceuticals: mechanisms, findings, and radiation dosimetry.
    Stabin MG; Breitz HB
    J Nucl Med; 2000 May; 41(5):863-73. PubMed ID: 10809203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
    Franklyn JA; Daykin J; Holder R; Sheppard MC
    QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A possible method using baseline hormonal levels to prescribe the appropriate oral therapeutic radioiodine dosage for Graves' disease.
    Nakajo M; Tsuchimochi S; Jinguji M; Tanabe H; Umanodan T; Nakabeppu Y
    Ann Nucl Med; 2007 Oct; 21(8):471-6. PubMed ID: 17952556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iodine prophylaxis intensification. Influence on radioiodine uptake and activity of 131I used in the treatment of hyperthyroid patients with Graves' disease.
    Baczyk M; Junik R; Ziemnicka K; Sowiński J
    Nuklearmedizin; 2005; 44(5):197-9. PubMed ID: 16395495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excretion of radionuclides in human breast milk after the administration of radiopharmaceuticals.
    Ahlgren L; Ivarsson S; Johansson L; Mattsson S; Nosslin B
    J Nucl Med; 1985 Sep; 26(9):1085-90. PubMed ID: 4032049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excretion of iodine-123-hippuran, technetium-99m-red blood cells, and technetium-99m-macroaggregated albumin into breast milk.
    Rose MR; Prescott MC; Herman KJ
    J Nucl Med; 1990 Jun; 31(6):978-84. PubMed ID: 2348243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of early (5 to 6 hours) iodine 123 uptake for diagnosis and treatment planning in Graves' disease.
    Hennessey JV; Berg LA; Ibrahim MA; Markert RJ
    Arch Intern Med; 1995 Mar; 155(6):621-4. PubMed ID: 7887758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of nuclear medicine in the management of Graves' disease.
    Freitas JE
    Q J Nucl Med; 1999 Dec; 43(4):297-306. PubMed ID: 10731780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapse of Graves' disease 23 years after treatment with radioactive iodine (131I).
    Hegele RA; Volpé R
    J Clin Lab Immunol; 1985 Oct; 18(2):103-5. PubMed ID: 3841162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
    Giovanella L; De Palma D; Ceriani L; Vanoli P; Garancini S; Tordiglione M; Tarolo GL
    Radiol Med; 2000 Dec; 100(6):480-3. PubMed ID: 11307510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.